ARS Pharmaceuticals Says EC Approves EURneffy for Emergency Treatment of Allergic Reactions

10:45 AM EDT, 08/26/2024 (MT Newswires) -- ARS Pharmaceuticals (SPRY) said Monday the European Commission has approved EURneffy for the emergency treatment of allergic reactions including anaphylaxis.

The adrenaline nasal spray will serve as the first needle-free treatment for severe allergies in the European Union for adults and children weighing 30 kilograms or more, many of whom may not carry, or delay using an injectable adrenaline product, the company said.

The company said EURneffy has 8 years of data protection, meaning no one else can use the data from its authorization application. It also 10 years of market protection, so no generic or similar versions can be sold in the EU during that time. The patents for its formula and treatment method in Europe will last until 2039.

ARS Pharma added it expects EURneffy to be available to patients in some EU countries in Q4 via an unidentified pharmaceutical company with an established presence in Europe.

Price: 12.85, Change: -0.11, Percent Change: -0.85